13 citations
,
February 2019 in “Türk oftalmoloji dergisi” New treatments for chronic central serous chorioretinopathy show promise in preventing permanent vision loss.
January 2016 in “e-Oftalmo CBO Revista Digital de Oftalmologia” The document reviewed central serous chorioretinopathy (CSC), focusing on its etiology, associated factors, diagnostic imaging, and therapeutic management. It highlighted the critical association of CSC with damage to mineralocorticoid receptors, psychological profiles, and glucocorticoid use. Various treatment options were discussed, including drugs like mineralocorticoid antagonists, rifampicin, finasteride, methotrexate, and propafenone. Preferred local therapies included photocoagulation, micropulse laser, and modified photodynamic therapy. The study aimed to provide therapeutic recommendations to prevent or minimize irreversible photoreceptor damage caused by CSC.
14 citations
,
September 2019 in “Eye” Some oral medications may help treat central serous chorioretinopathy, especially eplerenone, but more research is needed.
3 citations
,
January 2016 in “Elsevier eBooks” Steroid hormones are crucial for body functions and have various medical uses, but their misuse can lead to dependence.
18 citations
,
May 2020 in “Biomolecules” Spironolactone, a heart and liver drug, has new uses including cancer treatment, viral infection prevention, and skin condition improvement.